|
|||||
|
|
| 1例环磷酰胺用于合并肺间质纤维化的AASV患者的药学实践 | |
| 引用本文： | 尹冬虹 宋俊丽 段金菊 任志宏. 1例环磷酰胺用于合并肺间质纤维化的AASV患者的药学实践[J]. 中国药师, 2017, 0(2): 295-297 |
| 作者姓名： | 尹冬虹 宋俊丽 段金菊 任志宏 |
| 作者单位： | 1.山西医科大学第二医院 太原 030001；2.山西省肿瘤医院 |
| 摘 要： | 摘 要抗中性粒细胞胞浆抗体(ANCA)相关性小血管炎(AASV)的推荐一线治疗方案为糖皮质激素联合环磷酰胺，而环磷酰胺有明确引起肺间质纤维化(PF)的不良反应，对于临床上合并PF的AASV患者，在选用环磷酰胺时有无禁忌，本文结合1例合并PF的AASV患者环磷酰胺是否该继续使用进行分析。 |
| 关 键 词： | 临床药师 ；环磷酰胺； 肺间质纤维化；抗中性粒细胞胞浆抗体相关性血管炎 |
| 收稿时间： | 2016-07-08 |
| 修稿时间： | 2016-11-08 |
Pharmaceutical Practice in One AASV Patient with Pulmonary Fibrosis Treated with Cyclophosphamide |
|
| Yin Donghong,Song Junli,Duan Jinju,Ren Zhihong. Pharmaceutical Practice in One AASV Patient with Pulmonary Fibrosis Treated with Cyclophosphamide[J]. China Pharmacist, 2017, 0(2): 295-297 | |
| Authors: | Yin Donghong Song Junli Duan Jinju Ren Zhihong |
| Abstract: | ABSTRACTIt is recommended that cyclophosphamide combined with corticosteroids should be used as the first line treatment of ANCA (antineutrophil cytoplasmic antibody) associated with systemic vasculitis (AASV), however, cyclophosphamide has notable adverse reaction of causing pulmonary fibrosis (PF). In this paper, whether cyclophosphamide should be used in an AASF patient with PF was analyzed in order to decide whether AASV with PF is one of contraindications of cyclophosphamide in clinical practice. |
| Keywords: | Clinical pharmacists Cyclophosphamide Pulmonary fibrosis Antineutrophil cytoplasmic antibody associated with systemic vasculitis |
| 点击此处可从《中国药师》浏览原始摘要信息 | |
| 点击此处可从《中国药师》下载免费的PDF全文 | |